News Archives - Page 9 of 16 - Halberd Corporation

Aug 18 2021

Halberd Corporation’s VITA-SHIELD-MAX(TM) Available. Buy Now!

By Admin|2021-09-28T10:26:44-04:00August 18th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 18, 2021 – Halberd Corporation’s (OTC-PINK: "HALB") Nutraceutical product, Vita-Shield-MaxTM is now available on www.vitashieldmax.com. Vita-Shield-MaxTM is a specially formulated Nutraceutical to help maintain a healthy immune system. William A. Hartman, Halberd's Chairman, President & CEO, stated, “Halberd Corporation’s scientists put extensive research into the precise formulation of this neutraceutical product ...

Aug 16 2021

Halberd’s Disease Elimination Technology R&D at Youngstown State University (YSU) Draws Attention of CBS Affiliate WKBN

By Admin|2021-08-15T14:11:44-04:00August 16th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 16, 2021 – Halberd Corporation’s (OTC-PINK: "HALB") research at Youngstown State University (YSU) caught the attention of Youngstown, OH TV news station, WKBN, a CBS affiliate. The station’s 5:00PM newscast on Friday, August 13, 2021, included a segment on Halberd’s on-going research and testing of its groundbreaking, patent protected technology at ...

Aug 9 2021

Halberd Corporation’s VITA-SHIELD-MAX(TM) Immunity Support Product Shipped

By Admin|2021-08-08T15:07:13-04:00August 9th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 9, 2021 – Halberd Corporation (OTC-PINK: "HALB") reports Vita-Shield-MaxTM, has been shipped! With Covid-19 cases back on the rise fueled by the Delta Variant, this “Immunity Support Nutraceutical Product” is arriving at the right time. William A. Hartman, Halberd's Chairman, President & CEO, stated, “We will shortly begin selling Vita-Shield-MaxTM and ...

Jul 28 2021

Halberd Corporation Successfully Establishes Disease Eradication Proof-of-Concept – “Never Before Accomplished”

By Admin|2021-07-27T17:35:26-04:00July 28th, 2021|Featured, Investor News, News|0 Comments

A Major Step Towards the Elimination of Multiple Infectious Diseases and Possible Treatment for Alzheimer’s Disease/PTSD/CTE Jackson Center, PA, July 28, 2021 – Halberd Corporation (OTC-PINK: "HALB") establishes “proof of concept” taking a major step towards the elimination of multiple infectious diseases, such as, malaria, tuberculosis, sepsis, meningitis, and pandemics, among others, by successfully eliminating ...

Jul 22 2021

Halberd Corp. Advances the Elimination of Antigens Present in Alzheimer’s Disease & PTSD/Chronic Traumatic Encephalopathy

By Admin|2021-07-21T19:48:45-04:00July 22nd, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, July 22, 2021 – Halberd Corporation (OTC-PINK: "HALB") confirms the shipment of samples of metallic nanoparticles conjugated to Alzheimer’s Disease (AD) antibodies, Tau and Phosphorylated Tau. Having successfully conjugated the metallic nanoparticles (via its breakthrough patent-pending process), GreenBioAZ shipped the materials to Youngstown State University (YSU). At YSU, Dr. William G. Sturrus, ...

Jun 30 2021

Halberd Corp. Discovers a Proprietary Disease-Causing Antigen Removal Process

By Admin|2021-06-29T23:00:53-04:00June 30th, 2021|Featured, Investor News, News|0 Comments

Method Does Not Require Antibody Conjugated Metallic Nanoparticles Jackson Center, PA, June 30, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces a possible breakthrough method for the removal of the disease-causing antigen(s) that does not require the use of metallic nanoparticles conjugated to antibodies. This simplified method for the removal of disease-causing antigen(s) utilizes more conventional ...

Jun 21 2021

Halberd Corporation’s Proprietary Technology for Alzheimer’s Disease Enters Stage 4 of 7 Stage Process

By Admin|2021-06-20T21:56:56-04:00June 21st, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, June 21, 2021 – Halberd Corporation’s (OTC-PINK: "HALB") proprietary technology enters stage 4 to address Alzheimer’s Disease (and other potential diseases); eradicating the antibody-disease combination through radiofrequency waves or laser or other means. Currently, there is no known effective treatment for Alzheimer’s Disease which afflicts over 40 million people worldwide, equivalent to ...

Jun 16 2021

Halberd Corporation Successfully Conjugates Metallic Particles and Antibodies Against Alzheimer’s Disease-Associated Antigens

By Admin|2021-06-15T21:04:24-04:00June 16th, 2021|Featured, Investor News, News|0 Comments

Enables Extracorporeal Eradication of Pathogens from Cerebral Spinal Fluid Via Radio Frequency and/or Laser Emissive Energy Jackson Center, PA, June 16, 2021 – Halberd Corporation (OTC-PINK: "HALB") has successfully conjugated, Tau, Phosphorylated Tau and Beta Amyloid antibodies with gold-coated iron oxide nanoparticles in a patent-pending process. These three antigens, which are found in Cerebral Spinal ...

Jun 9 2021

Halberd Corporation Undertakes Process Toward the Elimination of Alzheimer’s Disease

By Admin|2021-06-08T21:47:47-04:00June 9th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, June 9, 2021 – Halberd Corporation (OTC-PINK: "HALB") commences experimentations to eradicate three of the principal components of Alzheimer’s Disease. By eliminating these three critical antigens, which form the basis for neurofibrillary tangles in the brain, Halberd believes that its patented extracorporeal treatment process can slow or stop the progress of the ...

Jun 7 2021

Halberd Corporation Creates Two New and Stronger SARS-CoV-2 Neutralizing Antibodies

By Admin|2021-06-06T20:44:05-04:00June 7th, 2021|Featured, Investor News, News|0 Comments

Demonstrates Greater Binding Affinity Than Previous Antibodies Jackson Center, PA, June 7, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful creation of two new neutralizing antibodies against the Spike Protein of SARS-CoV-2, both with a stronger binding affinity than Halberd’s earlier announced monoclonal antibodies against Covid-19. Each of these new antibodies bind to different ...

Previous 8910 Next